HOME >> MEDICINE >> NEWS
DDW Studies Present Evidence That Thalomid (Thalidomide) Is Active In Treating Crohn's Disease

ORLANDO, FL, May 19, 1999 -- Researchers investigating the use of THALOMIDR (thalidomide) to treat Crohn's disease today announced preliminary findings from a pilot study at the annual Digestive Disease WeekR meeting in Orlando, FL.

Lead investigator, Eric A. Vasiliauskas, M.D., associate clinical director of the Inflammatory Bowel Disease Center at Cedar's Sinai, Los Angeles reported findings from a pilot study of 12 patients at the Center. All patients had chronic, steroid-dependent or unresponsive Crohn's disease, an inflammatory disease of the intestinal tract.

According to Dr. Vasiliauskas, while all study participants felt better on the drug, two-thirds of the patients treated with THALOMID experienced a "significant improvement in their condition," as measured by the Crohn's Disease Activity Index (CDAI). The most common side effects reported were drowsiness and transient peripheral neuropathy. Celgene (NASDAQ: CELG) Corporation's THALOMID (thalidomide) was recently awarded orphan drug designation by the U.S. Food and Drug Administration (FDA).

"Although this was a pilot study, we did observe improvements in CDAI in these patients with Crohn's disease, which had been refractory to standard therapies," says Dr. Vasiliauskas. "In addition, these scores were maintained in most patients, even after steroids were tapered. Decreased fistula drainage and fistula closure was also observed in some patients. The data suggest that a Phase III study using thalidomide to treat Crohn's disease, should be conducted."

Dr. Vasiliauskas reported on the pilot study findings of 12 patients treated during a 12-week study with low-dose (50-100 mg per day) THALOMID (thalidomide). The Cedar's Sinai investigative team for this study also included Stephen R. Targan, M.D., director of the Inflammatory Bowel Disease Center.

In addition to this pilot study, other groups of researchers, including European and American investigative teams, are conducting tr
'"/>

Contact: Sandra Van
Sandy@VanCommunications.com
1-800-396-1002
Cedars-Sinai Medical Center
19-May-1999


Page: 1 2

Related medicine news :

1. Studies underscore genetic involvement in nicotine addiction & aggressive hostility
2. Studies address issues of risk and survival in rapidly increasing GI cancers
3. Studies examine coffee drinking and risk of liver and colorectal cancers
4. Studies reveal physicians attitudes on end-of-life care
5. Studies from the November issue of The Archives of Dermatology, a theme issue on facial rejuvenation
6. Studies link obesity to increased frequency of heartburn symptoms; greater risk of esophageal cancer
7. Studies demonstrate positive data in treatment of hepatitis C
8. Studies examine risk factors and potential consequences associated with prehypertension
9. Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
10. Studies identify risk factors for colon cancer
11. Studies indicate healthy eating may affect cancer development, improve digestive system

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... , ... September 01, 2020 , ... Feeding Matters ... for children with Pediatric Feeding Disorder (PFD), is pleased to announce that the U.S. ... stand-alone diagnostic code (R code) in the next edition of the U.S. International ...
(Date:8/31/2020)... ... ... out your dear friend has cancer? , It’s hard to hear your doctor say the ... Once the shock wears off, the questions and fears can be overwhelming. , How should ... help? Words are failing me. I’m scared. I want to DO something. , We’ve talked ...
(Date:8/31/2020)... IRVINE, Calif. (PRWEB) , ... August 31, 2020 ... ... providers of business support services to dental groups in the United States, today ... serving the community of Beaumont, CA. , Patients will enjoy convenient hours, ...
(Date:8/31/2020)... ... August 31, 2020 , ... Bonde Innovations, LLC, a venture-backed ... heart failure, today announced that the company has been awarded a Phase 1 ... National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). ...
(Date:8/28/2020)... , ... August 28, 2020 , ... ... Nourished Group set out to continue helping the specialty-diet community connect with ... new gluten-free products, get coupons, enter giveaways, chat with brands & watch over ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... August 27, 2020 , ... ... announced the successful completion of their 2020 System and Organizational Controls (SOC) 1® ... interim assessment and MARS-E compliance assessment. These achievements reflect their long-standing commitment to ...
(Date:8/27/2020)... ... August 27, 2020 , ... Trella ... Enquire, a leading provider of cloud CRM, marketing automation, and contact center solutions ... will involve the integration of Trella’s performance intelligence data and insights into Enquire’s ...
(Date:8/26/2020)... ... August 26, 2020 , ... AseptiScope, a privately funded San Diego, California ... Year by MedTech Outlook. , “AseptiScope is pleased to receive this recognition,” ... who wear gloves on their hands, goggles on their eyes, covers on their shoes, ...
Breaking Medicine Technology:
Cached News: